|
|
Volumn 8, Issue 9, 1999, Pages 1373-1384
|
|
Direct thrombin inhibitors: Current status and future prospects
|
|
Author keywords
Anticoagulants; Antithrombotics; Clinical trials; Hirudin; Thrombin; Thrombin inhibitors
|
|
Indexed keywords
1 (2 AMINO 6 METHYL 5 PYRIDINYLMETHYLAMINOCARBONYLMETHYL) 3 BENZYLSULFONAMIDO 6 METHYL 2 PYRIDINONE;
1 (6 AMINO 2 METHYL 3 PYRIDINYLMETHYLAMINOCARBONYLMETHYL) 3 PHENETHYLAMINO 6 METHYL 2 PYRAZINONE;
1 [3 (4 AMIDINOPHENYL) 2 (1,2,3,4 TETRAHYDRO 2 METHYL 7 ISOQUINOLINYLSULFONAMIDO)PROPIONYL] 1,2,3,6 TETRAHYDRO 4 METHYLPICOLINIC ACID;
ACETYLSALICYLIC ACID;
ALTEPLASE;
ANTICOAGULANT AGENT;
ARGATROBAN;
BMS 189664;
CORTHROMBIN;
DESULFATOHIRUDIN;
EFEGATRAN;
ENOXAPARIN;
HEPARIN;
HIRUDIN;
HIRULOG;
LEPIRUDIN;
LY 333545;
MELAGATRAN;
NAPSAGATRAN;
S 18326;
STREPTOKINASE;
THROMBIN;
THROMBIN INHIBITOR;
UNCLASSIFIED DRUG;
XIMELAGATRAN;
BIOAVAILABILITY;
BLOOD CLOT LYSIS;
BRAIN HEMORRHAGE;
CLINICAL TRIAL;
DRUG BIOAVAILABILITY;
DRUG HALF LIFE;
HEART INFARCTION;
HUMAN;
INTRAVENOUS DRUG ADMINISTRATION;
ORAL DRUG ADMINISTRATION;
REVIEW;
SUBCUTANEOUS DRUG ADMINISTRATION;
THROMBOSIS;
|
|
EID: 0032841949
PISSN: 13543784
EISSN: None
Source Type: Journal
DOI: 10.1517/13543784.8.9.1373 Document Type: Review |
|
Times cited : (27)
|
|
References (58)
|
